SEQUENT SCIENTIFIC
|
|
BOM : 512529     NSE : SEQUENT     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 26,2023 |
Price(EOD): βΉ 74.12
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 1,848.55 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SEQUENT SCIENTIFIC | -6.1% | 0.4% | -43.9% |
SUN PHARMACEUTICAL INDUSTRIES | 3.6% | -0.1% | 2.5% |
DIVIS LABORATORIES | 7.5% | 9% | -11.9% |
CIPLA | 2.8% | 4.3% | -2.7% |
DR REDDYS LABORATORIES | 1.7% | -6.5% | 5.3% |
TORRENT PHARMACEUTICALS | 2% | 5% | 30% |
ABBOTT INDIA | 2.5% | -1.9% | 23% |
ZYDUS LIFESCIENCES | 0.3% | -1.7% | 39.6% |
ALKEM LABORATORIES | 2.8% | -2.4% | 11.4% |
FUNDAMENTAL ANALYSIS OF SEQUENT SCIENTIFIC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SEQUENT SCIENTIFIC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-15.27
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -121.06 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 2.65
P/B Calculated based on Book Value of Rs 698.78 Cr
[Latest Year - Mar2023 - Consolidated Results ] 1.3
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,420.91 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
48% -21% 10% |
SHARE PRICE MOMENTUM OF SEQUENT SCIENTIFIC
SEQUENT SCIENTIFIC vs SENSEX
DEBT OF SEQUENT SCIENTIFIC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.02 0.01 0.04 0.02 |
0.49 0.31 0.51 0.44 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SEQUENT SCIENTIFIC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SEQUENT SCIENTIFIC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-2.3% -132.58% -770.69% -845.48% |
-4.44% -110.1% -589.24% -1033.74% |
QtrlyTrend |
-8 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
SEQUENT SCIENTIFIC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 3.3% | 3.6% | 2.6% |
S&P BSE MIDSMALLCAP | 2% | 6.8% | 16.6% |
S&P BSE ALLCAP | 1.9% | 5% | 12.9% |
S&P BSE SMALL CAP | 1.4% | 6.3% | 14.5% |
You may also like the below Video Courses
FAQ about SEQUENT SCIENTIFIC
Is SEQUENT SCIENTIFIC good for long term investment?
As on May 26,2023, the Fundamentals of SEQUENT SCIENTIFIC look Strong and hence it may be good for long term investment! See Financial Performance of SEQUENT SCIENTIFIC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SEQUENT SCIENTIFIC UnderValued or OverValued?
As on May 26,2023, SEQUENT SCIENTIFIC is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of SEQUENT SCIENTIFIC ?
As on May 26,2023, the Intrinsic Value of SEQUENT SCIENTIFIC is Rs. 67.60 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 49.99
Fair Value [Median EV / Sales Model] : Rs. 93.96
Fair Value [Median Price / Sales Model] : Rs. 67.60
Estimated Median Fair Value of SEQUENT SCIENTIFIC : Rs. 67.60
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is SEQUENT SCIENTIFIC trading at a Premium or Discount?
As on May 26,2023, SEQUENT SCIENTIFIC is trading at a Premium of 10% based on the estimates of Median Intrinsic Value!